Plasmacluster Ion Technology: Proven to Decrease Risk of Tuberculosis Infection
Tuberculosis is an infectious disease that affects the lung area. The infection normally spreads through person-t0-person transmission via coughing, sneezing, spitting, and talking. These motions from an infected person allow microscopic saliva droplets to go into the air.
Developing countries heavily affected by this disease includes the Philippines with over 290,000 Filipino victims every year. The World Health Organization has confirmed a total number of 9 million cases worldwide with yearly death tolls reaching up to 1.5 million.
The fight for its total wipe-out is a movement that should involve different institutions. From the government to the academe, and down to private organizations and corporations everyone must participate.
Together, Sharp and the WHO Global Health Workforce Alliance National Center of Tuberculosis and Lung Disease put together a team of experts to test and study the power of the Plasmacluster Ion Technology in preventing the spread and infection of Tuberculosis.
Plasmacluster Ion Technology, or PCI, is Sharp’s proprietary air purifying technology that uses positive and negative ions to deactivate the effects of airborne viruses, bacteria, allergens and microbes by up to 99%.
The study acquired the help of healthcare workers and patients from a special Tuberculosis hospital in Tbilisi, Georgia and placed 140 Sharp Plasmacluster Ion Technology devices in the vicinity.
Healthcare workers who tested negative carriers became the first core group of participants. They underwent the test again in the next months to check the effectivity of the devices.
49 patients resulted without ADR (Acquired Drug Resistance)1 from the 155 Tuberculosis culture positive patients after the initial Drug Susceptibility Test2. The 49 patients underwent the Plasmacluster Ion Technology trial to determine its efficacy in preventing ADR in culture-positive patients.
For both groups, the experiment came in with favorable results. The Plasmacluster Ion Technology reduced the risk of healthcare workers to carry the Tuberculosis bacteria. Only 1 out of 10 workers in the PCI-protected area tested as a positive carrier. The rooms without PCI resulted to 6 out of 15 positive carriers.
Results for ADR-positive patients decreased as well. The Plasmacluster Ion Technology-equipped room only generated 1 out of 25 patients. The rooms without the devices resulted to 4 out of 19 affected patients.
These results only prove that the Plasmacluster Ion Technology truly helps decrease the spread of Tuberculosis and aid culture positive patients in repressing ADR. These impressive findings paved the way for the researchers to secure an invitation to the 21st Congress of Asian Pacific Society of Respirology.
The Plasmacluster Ion Technology participated in over 28 academic trials. It has already proven itself effective in reducing the spread of other hazardous substances. These hazards include the influenza virus, drug-resistant bacteria, and mite allergens. It even lessens the risk of tracheal inflammation in childhood asthma patients.
Sharp’s involvement in various testings only attests to their dedication and passion in affirming the Plasmacluster Ion Technology’s effectivity. It challenges even its own engineering in order to serve the population better.